Related Experiment Videos
The effect of beta-adrenoreceptive antagonists on the morbidity and mortality in cardiovascular disease
Insights
Beta-blockers show no survival benefit for angina pectoris patients. While abrupt cessation may increase risks, evidence suggests beta-blockers improve survival in patients post-myocardial infarction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-adrenoreceptor antagonists are commonly used for cardiovascular conditions.
- Their long-term effects on morbidity and mortality in angina pectoris and myocardial infarction require critical review.
Purpose of the Study:
- To critically review the effects of chronic beta-adrenoreceptor antagonist administration on morbidity and mortality in angina pectoris and myocardial infarction.
- To evaluate the evidence regarding abrupt cessation of beta-blocker therapy.
- To assess the role of beta-blockers in different phases of myocardial infarction.
Main Methods:
- Systematic review and critical analysis of existing literature.
- Examination of studies on chronic beta-blocker administration.
- Analysis of data concerning angina pectoris and myocardial infarction outcomes.
Main Results:
- Inconclusive evidence exists that abrupt cessation of beta-blocker therapy may increase morbidity and mortality in angina pectoris.
- No evidence supports beta-antagonists prolonging life in angina pectoris patients.
- Beta-blockers reduce mortality in the acute phase of experimental myocardial infarction, but not in humans.
- Increasing evidence suggests beta-blockers prolong survival in patients surviving the acute phase of myocardial infarction.
Conclusions:
- The role of beta-blockers in angina pectoris requires further clarification, especially concerning abrupt cessation.
- Beta-blockers do not appear to prolong life in angina pectoris patients.
- Beta-blockers demonstrate a survival benefit for patients post-myocardial infarction, warranting further investigation.
Abstract:
The effect is critically reviewed of chronic administration of beta-adrenoreceptor antagonists on morbidity and mortality in angina pectoris and myocardial infarction. There is inconclusive evidence that the abrupt cessation of therapy with these agents may increase morbidity and mortality in angina pectoris. The type of anginal patient in which this may occur is not yet defined and neither is the mechanism. There is no evidence that beta-antagonists prolong the life of anginal patients. In the acute phase of experimental myocardial infarction, these drugs reduce mortality but do not do so in man. There is increasing evidence that they prolong life if administered to patients surviving the acute phase of myocardial infarction. The need for further studies is discussed.